Royalty Pharma Plc (RPRX)
39.34
+0.19
(+0.49%)
USD |
NASDAQ |
Dec 05, 11:51
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 16.81B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 53.74% |
| Valuation | |
| PE Ratio | 22.50 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 9.579 |
| Price to Book Value | 2.620 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.22 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.397 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 49.68% |
Profile
| Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY. |
| URL | http://royaltypharma.com |
| Investor Relations URL | https://www.royaltypharma.com/investors |
| HQ State/Province | New York |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Feb. 10, 2026 (est.) |
| Last Earnings Release | Nov. 05, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Nov. 14, 2025 |
Ratings
Profile
| Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY. |
| URL | http://royaltypharma.com |
| Investor Relations URL | https://www.royaltypharma.com/investors |
| HQ State/Province | New York |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Feb. 10, 2026 (est.) |
| Last Earnings Release | Nov. 05, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Nov. 14, 2025 |